DelveInsight Business Research LLP

DelveInsight has launched a new report on “Acute Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Acute Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

1. AML accounts for <3% of all cancers, and 25% of all leukemia in adults. Worldwide, the incidence of AML was reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years.

2. The incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood.  From 2000 to 2003, the US incidence rate in people age

3. The Surveillance has reported an AML incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%.

Key benefits of the report:

1. Acute Myeloid Leukemia market report covers a descriptive overview and comprehensive insight of the Acute Myeloid Leukemia Epidemiology and Acute Myeloid Leukemia  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Acute Myeloid Leukemia market report provides insights on the current and emerging therapies.

3. Acute Myeloid Leukemia market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Acute Myeloid Leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market.

Got queries? Click here to know more about Acute Myeloid Leukemia Market Landscape.

Acute Myeloid Leukemia Overview

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word “acute” in acute myelogenous leukemia denotes the disease’s rapid progression. It’s called myelogenous leukemia because it affects a group of white blood cells called the myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells, and platelets.

The key players involved in the Acute Myeloid Leukemia  market:

• Actinium Pharmaceuticals

• AVEO Oncology and Biodesix

• Rafael Pharmaceuticals

• BioSight

• BerGenBio

• Helsinn Healthcare

• And others

The launch of the emerging therapies is expected to significantly impact the Acute Myeloid Leukemia treatment scenario in the upcoming years:-

Drug covered

• omab-B CD45 and Actimab-A CD33 

• Ficlatuzumab 

• Devimistat

• BST236

• Bemcentinib

• Pracinostat

• And others.

Table of Contents:

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Acute Myeloid Leukemia  Patient Share (%) Overview at a Glance

5. Acute Myeloid Leukemia  Market Overview at a Glance

6. Acute Myeloid Leukemia  Disease Background and Overview

7. Acute Myeloid Leukemia  Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Myeloid Leukemia 

9. Acute Myeloid Leukemia  Current Treatment and Medical Practices

10. Unmet Needs

11. Acute Myeloid Leukemia  Emerging Therapies

12. Acute Myeloid Leukemia  Market Outlook

13. Country-Wise Acute Myeloid Leukemia  Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Acute Myeloid Leukemia  Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Acute Myeloid Leukemia Pipeline 

“Acute Myeloid Leukemia Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Acute Myeloid Leukemia market. A detailed picture of the  Acute Myeloid Leukemia pipeline landscape is provided, which includes the disease overview and  Acute Myeloid Leukemia treatment guidelines.

Acute Myeloid Leukemia Epidemiology

DelveInsight’s ‘Acute Myeloid Leukemia  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Acute Myeloid Leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/